Clinical Trials Directory

Trials / Completed

CompletedNCT03415009

Prevalence of IL28B Polymorphism in Hepatitis C Patients

Prevalence of IL28B Polymorphism in Hepatitis C Patients in Singapore and Its Effect on the Outcome of Hepatitis C Treatment

Status
Completed
Phase
Study type
Observational
Enrollment
39 (actual)
Sponsor
Changi General Hospital · Academic / Other
Sex
All
Age
21 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Response to peginterferon and ribavirin treatment in hepatitis C (HCV) depends on viral and host factors. Single nucleotide polypmorphisms (SNP) near to IL28B gene (especially at rs12979860 and rs8099917) are strongly associated with the response to treatment in HCV genotype 1 infection, less so in HCV genotype 2/3 infection. CC genotype in rs12979860 and TT genotype at rs8099917 are associated with good treatment outcome. Asian populations have high prevalence of CC genotype in other studies, which can explain relatively good response to peginterferon/ ribavirin in genotype 1 infection in Asians compared with Caucasians.

Detailed description

The prevalence of different genotypes of IL28B polymorphism in the local population will be studied. DNA will be extracted from the whole blood sample of hepatitis C patients with genotype 1, 2 and 3 infection. It will be amplified by real-time PCR and subsequently analysed for the genotypes of IL28B SNPs.

Conditions

Timeline

Start date
2014-06-01
Primary completion
2016-06-01
Completion
2016-12-01
First posted
2018-01-30
Last updated
2018-01-30

Locations

1 site across 1 country: Singapore

Source: ClinicalTrials.gov record NCT03415009. Inclusion in this directory is not an endorsement.